GatePass Capital LLC Lowers Holdings in Pfizer Inc. $PFE

GatePass Capital LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 52.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,129 shares of the biopharmaceutical company’s stock after selling 25,887 shares during the quarter. GatePass Capital LLC’s holdings in Pfizer were worth $576,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after acquiring an additional 7,031,162 shares during the period. State Street Corp lifted its holdings in shares of Pfizer by 0.9% during the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after acquiring an additional 2,786,098 shares during the period. Northern Trust Corp lifted its holdings in shares of Pfizer by 1.4% during the 3rd quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock worth $1,631,225,000 after acquiring an additional 869,175 shares during the period. Fisher Asset Management LLC lifted its holdings in shares of Pfizer by 5.4% during the 4th quarter. Fisher Asset Management LLC now owns 51,952,106 shares of the biopharmaceutical company’s stock worth $1,293,607,000 after acquiring an additional 2,664,052 shares during the period. Finally, Legal & General Group Plc lifted its holdings in shares of Pfizer by 2.7% during the 4th quarter. Legal & General Group Plc now owns 42,864,225 shares of the biopharmaceutical company’s stock worth $1,067,319,000 after acquiring an additional 1,123,039 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Up 0.1%

PFE opened at $25.92 on Tuesday. The firm has a 50 day moving average price of $26.84 and a 200 day moving average price of $26.25. The company has a market cap of $147.72 billion, a PE ratio of 19.79 and a beta of 0.35. Pfizer Inc. has a 1 year low of $22.88 and a 1 year high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the prior year, the company earned $0.92 EPS. The company’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.6%. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on PFE shares. Royal Bank Of Canada reiterated an “underperform” rating and set a $25.00 price objective on shares of Pfizer in a report on Monday, April 20th. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. CICC Research started coverage on shares of Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective on the stock. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Finally, HSBC increased their target price on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average price target of $28.61.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.